Pitch deck available on demand
Cancertain: Saving Cancer Patients’ Lives. Optimising Treatment. Bespoke Drug Panel Test using proprietary scaffold 3D-patient cell screening. Testing for all solid cancers through non-invasive blood analysis +/- tumour biopsy. Comprehensive testing for standard and targeted chemotherapies and immunotherapies.
Seeking: Strategic investors in the global company who can also be the commercial partner to grow the MENA market.
Imspex: Imspex has developed two proprietary platform instruments, each capable of addressing testing needs of a range of clinical diseases and industrial testing markets. There are currently 2 instruments, BreathSpec® - a non-invasive breath analyser and FlavourSpec® - liquid sample testing using automated headspace testing. Imspex is the global leader in breath testing analysis and its COVID-19 test is in multi-site clinical validation with related CE approval process anticipated mid-2021. Sales are increasing monthly to a range of international markets projected to deliver profitable revenue of over €10M in 2021.
Seeking: Strategic investors in the global company who can also be the commercial partner to grow the MENA market.
Ostara: Innovation for reproductive success. Ostara will deliver end-to-end fertility solutions through the Ostara Fertility Pathway™, proprietary innovative technologies and a clinically validated product pipeline, all supported by digital access to user-friendly information and professional support.
Seeking: Strategic investors in the global company who can also be the commercial partner to grow the MENA market.
Digostics: Transforming the detection of diabetes through accurate home testing. GTT@home from Digostics is the world’s first direct replacement for the gold standard and exclusively clinic-basedoral glucose tolerance test, OGTT.
Seeking: Strategic commercial partner/s to grow the MENA market.